Companies › Shanghai Lanyi Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Hematology, Metabolic and endocrine; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EA5 humanized monoclonal antibody | – | Phase 1 | PNH - Paroxysmal Nocturnal Hemoglobinuria; Antiphospholipid Syndrome (APS) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07256301 | EA5 | Phase 1 | PNH - Paroxysmal Nocturnal Hemoglobinuria | Hematology | Aug 2026 |
| NCT07632976 | EA5 | Phase 1 | Antiphospholipid Syndrome (APS) | Metabolic and endocrine | Sep 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.